{"id":"etavopivat-tablets-low-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108580","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etavopivat is a KCNQ1 potassium channel activator that promotes the differentiation of erythroid progenitor cells toward fetal hemoglobin-producing cells. By increasing HbF levels, the drug reduces sickling and hemolysis in patients with sickle cell disease, thereby reducing vaso-occlusive crises and other complications associated with the disease.","oneSentence":"Etavopivat activates the KCNQ1 potassium channel to increase fetal hemoglobin (HbF) production in red blood cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:41.946Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sickle cell disease"}]},"trialDetails":[{"nctId":"NCT04624659","phase":"PHASE3","title":"A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Forma Therapeutics, Inc.","startDate":"2021-01-29","conditions":"Sickle Cell Disease","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FT-4202"],"phase":"phase_3","status":"active","brandName":"Etavopivat Tablets Low dose","genericName":"Etavopivat Tablets Low dose","companyName":"Forma Therapeutics, Inc.","companyId":"forma-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etavopivat activates the KCNQ1 potassium channel to increase fetal hemoglobin (HbF) production in red blood cells. Used for Sickle cell disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}